Skip to content
Triangle logo TriangleGet started
← Childhood Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Other clinical trials

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents / Treatment Options Under Clinical Evaluation

Anti–PD-1 antibodies being studied in children with Hodgkin lymphoma include the following:

Pembrolizumab (NCT02332668).

Source links and citations

Studies cited in this source section

Source citation is not a determination that a study applies to you.

Preserved source evidence · Not medical advice